AbCellera Biologics (ABCL) Institutional Ownership
13F filers reported holding 42.5% of AbCellera Biologics (ABCL) shares as of Sep 30, 2026, across 164 filers.
- Held by 13F filers
- 42.5%
- Sep 30, 2026
- 13F filers
- 164
- quarter ended Sep 30, 2026
- 13F value
- $2.0B
- 139.0M shares
- Quarter's fund flow
- Mild accumulation
- 45 new · 31 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Booth Andrew | Chief Financial Officer | Acquired · Option exercise | 50,000Common Shares | $0.32 | ↗ |
| Nov 13, 2026 | Booth Andrew | Chief Financial Officer | Disposed · Gift | 50,000Common Shares | — | ↗ |
| Nov 13, 2026 | Booth Andrew | Chief Financial Officer | Disposed · Option exercise | 50,000Share option (right to buy) | — | ↗ |
| Nov 13, 2026 | Thermopylae Holdings Ltd. | 10% owner | Disposed · Gift | 125,000Common Shares | — | ↗ |
| Nov 13, 2026 | Booth Andrew | Chief Financial Officer | Acquired · Open-market buy | 8,600Common Shares | $11.33 | ↗ |
| Nov 12, 2026 | Thermopylae Holdings Ltd. | 10% owner | Acquired · Open-market buy | 60,565Common Shares | $11.54 | ↗ |
| Aug 24, 2026 | Hayden Michael R | director | Acquired · Open-market buy | 53,613Common Shares | $10.64 | ↗ |
| Aug 18, 2026 | Montalbano John S. | director | Acquired · Open-market buy | 10,000Common Shares | $11.03 | ↗ |
| Aug 14, 2026 | Booth Andrew | Chief Financial Officer | Acquired · Open-market buy | 37,200Common Shares | $10.32 | ↗ |
| Aug 12, 2026 | Hayden Michael R | director | Acquired · Open-market buy | 46,387Common Shares | $10.37 | ↗ |
| Aug 11, 2026 | Hayden Michael R | director | Disposed · Gift | 50,000Common Shares | — | ↗ |
| Jul 1, 2026 | Seely Lynn | director | Acquired · Grant / award | 152,207Share option (right to buy) | — | ↗ |
| Jul 1, 2026 | Sandor Victor | director | Acquired · Grant / award | 152,207Share option (right to buy) | — | ↗ |
| Jun 11, 2026 | Montalbano John S. | director | Acquired · Grant / award | 111,701Share option (right to buy) | — | ↗ |
| Jun 11, 2026 | Quake Stephen | director | Acquired · Grant / award | 111,701Share option (right to buy) | — | ↗ |
| Jun 11, 2026 | Hayden Michael R | director | Acquired · Grant / award | 111,701Share option (right to buy) | — | ↗ |
| Jun 3, 2026 | Booth Andrew | Chief Financial Officer | Acquired · Option exercise | 250,000Common Shares | $0.19 | ↗ |
| Jun 3, 2026 | Booth Andrew | Chief Financial Officer | Disposed · Option exercise | 250,000Share option (right to buy) | — | ↗ |
| May 14, 2026 | Montalbano John S. | director | Acquired · Open-market buy | 20,000Common Shares | $4.77 | ↗ |
| Feb 27, 2026 | Thermopylae Holdings Ltd. | 10% owner | Acquired · Open-market buy | 38,000Common Shares | $3.44 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of AbCellera Biologics do institutions hold?
13F filers reported holding 42.5% of AbCellera Biologics' shares as of Sep 30, 2026, across 164 filers.
How many 13F filers hold AbCellera Biologics?
AbCellera Biologics was held by 164 13F filers as of Sep 30, 2026.
Not investment advice.

